-
Global Biopharma Layoffs March 2026
Layoffs
Global Biopharma companies including Merck, Baye, and Novartis announce workforce reductions in March 2026 as part of cost-saving and strategic realignments, impacting research, technology, and leadership roles across their operations.
-
Global Biopharma Layoffs January 2026
Layoffs
This article tracks recent biotech and pharma layoffs, including major workforce cuts at Voyager Therapeutics, Intercept Pharmaceuticals, Mythic Therapeutics, Pfizer, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
-
Global Biopharma Layoffs October 2025
Layoffs
This article tracks recent biotech and pharma layoffs, including major workforce cuts at Novo Nordisk, Takeda, GSK, Pharming, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
-
Takeda's 2024 Financial report
Market Trend
Takeda projects $11B in peak sales from three key drug candidates—TAK-279, TAK-861, and TAK-121—while restructuring its pipeline to drive future growth and profitability.
-
Takeda Shuts Down EGFR, B7-H3 Programs
Takeda
Takeda announces major R&D cuts, discontinuing EGFR and B7-H3 oncology projects from its $525M Maverick deal, and streamlining other pipelines to focus on high-potential therapies.
-
Takeda's 2024 Q4 Financial report
Market Trend
Takeda's 2024 fiscal report shows 7.4% revenue growth to ￥4.58T, driven by strong core business and R&D breakthroughs. Key segments include GI, rare diseases, oncology. Outlook for 2025 remains stable despite VYVANSE competition.
-
-
Takeda 2024 Q3 Financial Report
Financial statements
Takeda’s 2024 financial report shows a $290M revenue for Fuquatinib and strong growth across its key segments. The company also announces CEO succession with Julie Kim to succeed Christophe Weber in 2026.
-
Top 10 Immunology Drugs to Watch in 2024
AbbVie
Explore the top 10 best-selling immunology drugs of 2023, including Humira, Dupixent, Stelara, and more. Discover how these innovative therapies are shaping the market, driving clinical breakthroughs, and overcoming competitive challenges.
-
Takeda Q2 2024 Financial Results
Financial statements
Takeda's Q2 2024 results show strong performance with total revenue of 2.384 trillion yen and upgraded full-year forecasts. Key highlights include Fruquintinib's overseas sales reaching 23.1 billion yen, driven by significant growth in the U.S. market.
主站蜘蛛池模板：
久久综合一区二区
|
精品久久久久久亚洲综合网站
|
国产福利片在线观看
|
四虎永久免费在线
|
国产精品久久久久久久久免费看
|
久久视频国产
|
日韩日日夜夜
|
99精品视频在线播放免费
|
欧美片网站免费
|
三级黄色片网站
|
亚洲一二三在线观看
|
最近日本中文字幕
|
波多野结衣一二区
|
狠狠爱夜夜
|
青青操在线观看
|
av黄色网
|
www欧美|
天天cao|
美女免费av|
中文在线资源
|
zjzjzjzjzj亚洲女人
|
日韩高清毛片
|
在线观看免费高清视频
|
免费观看日批视频
|
国产精品视频免费看
|
国产精品1234区
|
99国产精品久久久久久久
|
国产成人精品久久二区二区91
|
免费特级毛片
|
欧美aⅴ视频
|
国产成人精品一区二区三区在线
|
亚洲成人免费
|
中文字幕手机在线观看
|
日韩有码在线视频
|
亚洲欧美国产精品专区久久
|
天堂资源站
|
中文字幕网站在线观看
|
国产成人精品在线视频
|
日本一区二区在线视频
|
黄色一级免费网站
|
日韩在线视频网址
|
